Mouse Monoclonal TNFRSF11B Antibody

TNFRSF11B, also known as osteoprotegerin (OPG), is a member of the tumor necrosis factor receptor superfamily encoded by the TNFRSF11B gene. It plays a critical role in regulating bone metabolism by acting as a decoy receptor for RANKL (receptor activator of nuclear factor-κB ligand), thereby inhibiting osteoclast differentiation and bone resorption. Dysregulation of TNFRSF11B is implicated in bone-related disorders such as osteoporosis, Paget’s disease, and bone metastases in cancers. Antibodies targeting TNFRSF11B are valuable tools for studying its expression, interaction with RANKL, and involvement in pathological processes. In research, these antibodies are used in techniques like ELISA, Western blot, and immunohistochemistry to quantify protein levels or localize OPG in tissues. Therapeutically, anti-TNFRSF11B antibodies have been explored to modulate bone remodeling in diseases characterized by excessive resorption or abnormal mineralization. Additionally, they aid in understanding the RANKL/RANK/OPG signaling axis, which influences not only bone homeostasis but also immune regulation and vascular health. Their development highlights the intersection of molecular biology, immunology, and clinical applications in managing skeletal and systemic diseases.